Teplizumab - preventative approaches to type 1 diabetes mellitus

被引：0
作者：
Seewoodhary, Jason [1 ]
Silveira, Angela [2 ]
机构：
[1] NHS Northwest London, Brent Integrated Hlth Board, London, England
[2] Saskatchewan Hlth Author, Publ Hlth & Prevent Med, Saskatoon, SK, Canada
来源：
PRACTICAL DIABETES | 2023年 / 40卷 / 02期
关键词：
teplizumab; type 1 diabetes mellitus; immunotherapy; anti-CD3; screening; INSULIN; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immunotherapies offer the potential to reprogramme the immune system to halt autoimmune destruction of insulin-producing beta-cells within the pancreas, dealing with the root cause of type 1 diabetes (T1DM) for the first time. Leading on from this, teplizumab, the first drug in this class, has been found to delay the onset of T1DM by an average of three years in people stratified high risk for developing T1DM. This review will critically consider the evidence basis underlying the utility of teplizumab in the management of T1DM. Copyright (c) 2023 John Wiley & Sons.
引用
收藏
页码：35 / +
页数：5
相关论文
共 50 条
  • [31] Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7years from diagnosis
    Perdigoto, Ana Luisa
    Preston-Hurlburt, Paula
    Clark, Pamela
    Long, S. Alice
    Linsley, Peter S.
    Harris, Kristina M.
    Gitelman, Steven E.
    Greenbaum, Carla J.
    Gottlieb, Peter A.
    Hagopian, William
    Woodwyk, Alyssa
    Dziura, James
    Herold, Kevan C.
    DIABETOLOGIA, 2019, 62 (04) : 655 - 664
  • [32] Diabetes mellitus-associated periodontitis: differences between type 1 and type 2 diabetes mellitus
    Aspriello, S. D.
    Zizzi, A.
    Tirabassi, G.
    Buldreghini, E.
    Biscotti, T.
    Faloia, E.
    Stramazzotti, D.
    Boscaro, M.
    Piemontese, M.
    JOURNAL OF PERIODONTAL RESEARCH, 2011, 46 (02) : 164 - 169
  • [33] Current developments in the prevention of type 1 diabetes
    Hommel, Angela
    Reschke, Felix
    DIABETOLOGE, 2021, 17 (06): : 657 - 666
  • [34] Current developments in the prevention of type 1 diabetes
    Hommel, Angela
    Reschke, Felix
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2021, 14 (04): : 150 - 158
  • [35] Prediction and prevention of Type 1 diabetes mellitus
    Zhang, Li
    Eisenbarth, George S.
    JOURNAL OF DIABETES, 2011, 3 (01) : 48 - 57
  • [36] Otelixizumab in the treatment of Type 1 diabetes mellitus
    Sprangers, Ben
    Van der Schueren, Bart
    Gillard, Pieter
    Mathieu, Chantal
    IMMUNOTHERAPY, 2011, 3 (11) : 1303 - 1316
  • [37] Type 1 diabetes mellitus and coronary revascularization
    Mamet, Helene
    Petrie, Mark C.
    Rocchiccioli, Paul
    CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2019, 8 (01) : 35 - 38
  • [38] Adolescent type 1 diabetes mellitus in India
    Ovais, Mohd
    Kamil, Mohd
    CURRENT SCIENCE, 2023, 124 (07): : 790 - 798
  • [39] Humoral responses in Type 1 diabetes mellitus
    Falorni, A
    Calcinaro, F
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2003, 4 (03) : 281 - 290
  • [40] Insulin therapy for diabetes mellitus type 1
    Dreyer, M.
    DIABETOLOGE, 2014, 10 (06): : 453 - 459
12345